Nifty
Sensex
:
:
12987.00
44259.74
128.60 (1.00%)
431.64 (0.98%)

Pharmaceuticals & Drugs - API

Rating :
72/99  (View)

BSE: 540222 | NSE: LAURUSLABS

292.35
6.90 (2.42%)
26-Nov-2020 | 4:02PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  295.00
  •  298.80
  •  289.30
  •  285.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4631170
  •  13539.23
  •  344.90
  •  59.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 15,278.54
  • 25.56
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 16,333.67
  • 0.18%
  • 6.98

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 32.12%
  • 8.89%
  • 27.84%
  • FII
  • DII
  • Others
  • 20.74%
  • 5.37%
  • 5.04%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 9.76
  • 11.26

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 9.28
  • 6.43

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 13.73
  • 15.05

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 30.51

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 3.42

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 13.46

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
1,139
712
60%
974
551
77%
839
635
32%
730
529
38%
Expenses
765
575
33%
696
467
49%
647
523
24%
581
442
32%
EBITDA
374
138
171%
278
83
234%
192
112
71%
148
88
69%
EBIDTM
33%
19%
29%
15%
23%
18%
20%
17%
Other Income
5
1
276%
7
4
58%
2
2
4%
2
1
35%
Interest
14
26
-46%
15
23
-33%
21
18
18%
21
24
-12%
Depreciation
51
48
7%
49
46
6%
46
43
6%
48
43
11%
PBT
314
66
378%
221
19
1042%
127
53
141%
82
23
259%
Tax
72
9
681%
50
4
1058%
17
9
77%
8
5
66%
PAT
242
57
328%
172
15
1038%
110
43
155%
73
18
312%
PATM
21%
8%
18%
3%
13%
7%
10%
3%
EPS
4.52
1.06
326%
3.20
0.28
1043%
2.06
0.81
154%
1.37
0.33
315%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
3,682
2,832
2,292
2,056
1,905
1,778
1,327
1,160
Net Sales Growth
52%
24%
11%
8%
7%
34%
14%
 
Cost Of Goods Sold
1,726
1,383
1,225
1,056
989
1,000
821
720
Gross Profit
1,956
1,449
1,067
1,000
915
777
505
439
GP Margin
53%
51%
47%
49%
48%
44%
38%
38%
Total Expenditure
2,690
2,267
1,936
1,643
1,497
1,415
1,131
956
Power & Fuel Cost
-
137
109
94
66
58
50
35
% Of Sales
-
5%
5%
5%
3%
3%
4%
3%
Employee Cost
-
321
276
238
205
175
131
103
% Of Sales
-
11%
12%
12%
11%
10%
10%
9%
Manufacturing Exp.
-
240
179
151
139
107
81
48
% Of Sales
-
8%
8%
7%
7%
6%
6%
4%
General & Admin Exp.
-
114
97
73
65
49
28
27
% Of Sales
-
4%
4%
4%
3%
3%
2%
2%
Selling & Distn. Exp.
-
62
32
24
23
16
12
13
% Of Sales
-
2%
1%
1%
1%
1%
1%
1%
Miscellaneous Exp.
-
11
17
6
9
9
7
10
% Of Sales
-
0%
1%
0%
0%
1%
1%
1%
EBITDA
992
565
356
413
408
362
195
204
EBITDA Margin
27%
20%
16%
20%
21%
20%
15%
18%
Other Income
16
6
16
29
33
4
34
9
Interest
70
90
88
80
100
111
101
59
Depreciation
193
187
164
125
106
86
62
33
PBT
744
294
120
237
235
169
67
121
Tax
147
38
26
70
44
35
-2
24
Tax Rate
20%
13%
22%
29%
19%
21%
-2%
20%
PAT
598
255
94
168
191
134
68
97
PAT before Minority Interest
598
255
94
168
191
134
68
97
Minority Interest
0
0
0
0
0
0
0
0
PAT Margin
16%
9%
4%
8%
10%
8%
5%
8%
PAT Growth
351%
172%
-44%
-12%
43%
97%
-30%
 
EPS
11.15
4.76
1.75
3.13
3.57
2.50
1.27
1.81

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
1,770
1,558
1,483
1,330
857
722
358
Share Capital
107
106
106
106
82
82
78
Total Reserves
1,658
1,447
1,371
1,219
771
637
277
Non-Current Liabilities
214
295
174
132
428
364
204
Secured Loans
165
259
142
125
354
304
188
Unsecured Loans
0
0
0
0
106
0
0
Long Term Provisions
46
30
21
15
7
5
4
Current Liabilities
1,692
1,424
1,307
1,121
884
802
711
Trade Payables
616
488
312
263
248
231
227
Other Current Liabilities
261
244
231
199
141
133
164
Short Term Borrowings
791
684
759
644
481
432
312
Short Term Provisions
25
7
5
14
14
7
7
Total Liabilities
3,676
3,278
2,964
2,584
2,169
1,888
1,273
Net Block
1,726
1,629
1,481
1,230
1,021
801
499
Gross Block
2,386
2,105
1,794
1,419
1,106
986
623
Accumulated Depreciation
659
476
313
189
85
185
124
Non Current Assets
1,864
1,815
1,716
1,444
1,166
1,024
697
Capital Work in Progress
67
110
163
143
70
110
116
Non Current Investment
3
3
3
3
7
7
0
Long Term Loans & Adv.
41
26
29
26
29
94
68
Other Non Current Assets
27
47
40
41
39
12
13
Current Assets
1,812
1,463
1,248
1,140
1,003
862
575
Current Investments
0
0
0
0
0
0
0
Inventories
905
682
585
509
487
476
328
Sundry Debtors
791
710
571
568
445
285
195
Cash & Bank
2
3
3
4
29
59
23
Other Current Assets
114
33
31
34
42
43
29
Short Term Loans & Adv.
62
35
59
25
24
23
20
Net Current Assets
120
39
-59
19
119
60
-136
Total Assets
3,676
3,278
2,964
2,584
2,169
1,888
1,273

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
347
298
342
332
182
-65
121
PBT
294
120
237
235
169
67
121
Adjustment
293
248
216
199
201
136
83
Changes in Working Capital
-200
-44
-49
-52
-154
-251
-59
Cash after chg. in Working capital
387
323
404
382
215
-48
145
Interest Paid
0
0
0
0
0
0
0
Tax Paid
-40
-25
-62
-50
-33
-17
-23
Other Direct Exp. Paid
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
Cash From Investing Activity
-221
-253
-384
-289
-312
-397
-312
Net Fixed Assets
-234
-255
-394
-354
-77
-354
Net Investments
0
-7
-1
-24
-7
-19
Others
13
9
12
90
-228
-24
Cash from Financing Activity
-128
-45
42
-54
103
486
203
Net Cash Inflow / Outflow
-1
0
1
-10
-27
24
12
Opening Cash & Equivalents
3
3
2
13
40
15
3
Closing Cash & Equivalent
2
3
3
2
13
40
15

Financial Ratios

Standalone /

Consolidated
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
33
29
139
125
499
420
189
ROA
7%
3%
6%
8%
7%
4%
8%
ROE
15%
6%
12%
18%
19%
14%
33%
ROCE
14%
8%
14%
17%
16%
14%
20%
Fixed Asset Turnover
1.26
1.18
1.29
1.53
1.73
1.66
1.87
Receivable days
97
102
100
96
74
65
61
Inventory Days
102
101
96
94
97
110
103
Payable days
80
73
61
59
59
69
87
Cash Conversion Cycle
119
130
136
131
112
106
77
Total Debt/Equity
0.60
0.67
0.66
0.64
1.20
1.14
1.54
Interest Cover
4
2
4
3
3
2
3

News Update


  • Laurus Labs signs definitive agreements to acquire majority stake in Richcore
    25th Nov 2020, 17:28 PM

    This acquisition marks Laurus Labs’ entry into the broader biologics and biotechnology segments

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.